Last reviewed · How we verify
Hydroxychloroquine + Prednisone
Hydroxychloroquine suppresses immune activation and inflammatory responses, while prednisone provides corticosteroid-mediated immunosuppression and anti-inflammatory effects.
Hydroxychloroquine suppresses immune activation and inflammatory responses, while prednisone provides corticosteroid-mediated immunosuppression and anti-inflammatory effects. Used for Autoimmune or inflammatory conditions (specific indication not publicly detailed for this Phase 3 trial).
At a glance
| Generic name | Hydroxychloroquine + Prednisone |
|---|---|
| Sponsor | University of Milano Bicocca |
| Drug class | Antimalarial + Corticosteroid combination |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Hydroxychloroquine is an antimalarial agent that accumulates in lysosomes and reduces antigen presentation and T-cell activation, making it effective in autoimmune diseases. Prednisone is a systemic corticosteroid that broadly suppresses immune cell function and inflammatory cytokine production. Together, this combination targets multiple pathways of immune dysregulation.
Approved indications
- Autoimmune or inflammatory conditions (specific indication not publicly detailed for this Phase 3 trial)
Common side effects
- Retinopathy
- Immunosuppression / increased infection risk
- Gastrointestinal disturbance
- Hyperglycemia
- Osteoporosis
Key clinical trials
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants (PHASE2)
- Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF (PHASE3)
- Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis (PHASE4)
- Immune-Mediated Pathophysiology And Clinical Triage Program (PHASE2)
- Chinese Rheumatism Biobank(CRB)
- The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis (PHASE2)
- IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |